Cargando…

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

In BRAF(V600mut) metastatic melanoma, the combination of BRAF and MEK inhibitors (BRAFi, MEKi) has undergone multiple resistance mechanisms, limiting its clinical benefit and resulting in the need for response predicting biomarkers. Based on phase III clinical trial data, several studies have previo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Louveau, Baptiste, Jouenne, Fanelie, Reger de Moura, Coralie, Sadoux, Aurelie, Baroudjian, Barouyr, Delyon, Julie, Herms, Florian, De Masson, Adele, Da Meda, Laetitia, Battistella, Maxime, Dumaz, Nicolas, Lebbe, Celeste, Mourah, Samia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721518/ https://www.ncbi.nlm.nih.gov/pubmed/31426590 http://dx.doi.org/10.3390/cancers11081203

Ejemplares similares

Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma
por: Reger de Moura, Coralie, et al.
Publicado: (2019)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors
por: Louveau, Baptiste, et al.
Publicado: (2019)

Atypical BRAF and NRAS Mutations in Mucosal Melanoma
por: Dumaz, Nicolas, et al.
Publicado: (2019)

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020)

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
por: Landras, Alexandra, et al.
Publicado: (2019)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma
por: Tétu, Pauline, et al.
Publicado: (2020)

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma
por: Pesqué, Louise, et al.
Publicado: (2022)

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
por: HERMS, Florian, et al.
Publicado: (2022)

18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors
por: Rivas, Alexia, et al.
Publicado: (2022)

HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E
por: Cheng, Lingxiao, et al.
Publicado: (2017)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Lack of evidence for the involvement of Merkel cell polyomavirus in pulmonary Langerhans cell histiocytosis
por: Jouenne, Fanélie, et al.
Publicado: (2020)

Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans
por: Beaziz, Jessica, et al.
Publicado: (2021)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

Correction: Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Julie, Delyon, et al.
Publicado: (2016)

Validation of a preclinical model for assessment of drug efficacy in melanoma
por: Delyon, Julie, et al.
Publicado: (2016)

Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes
por: Nguyen, Thuy Thi, et al.
Publicado: (2020)

Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis
por: Roeser, Anais, et al.
Publicado: (2022)

Systemic Treatment Initiation in Classical and Endemic Kaposi’s Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study
por: Benajiba, Lina, et al.
Publicado: (2021)

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?
por: Lakhmiri, Myriam, et al.
Publicado: (2018)

A Novel Case of Gorlin Syndrome Mosaicism Involving an SMO Gene Mutation: Clinical, Histological and Molecular Analysis of Basaloid Tumours
por: IGHILAHRIZ, Meriem, et al.
Publicado: (2021)

CD147 Promotes Tumor Lymphangiogenesis in Melanoma via PROX-1
por: Reger de Moura, Coralie, et al.
Publicado: (2021)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling
por: Hamis, Sara J., et al.
Publicado: (2021)

Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients
por: Cuzzubbo, Stefania, et al.
Publicado: (2020)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Gauci, Marie-Léa, et al.
Publicado: (2021)

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition
por: Rowdo, Florencia Paula Madorsky, et al.
Publicado: (2020)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

HGG-47. DECREASED GROWTH VELOCITY WITH LONG TERM USE OF BRAFV600e AND MEK INHIBITION IN A PATIENT WITH ANAPLASTIC GANGLIOGLIOMA
por: Tran, Hung, et al.
Publicado: (2020)

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade
por: Penna, Ilaria, et al.
Publicado: (2015)

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma
por: Satzger, Imke, et al.
Publicado: (2015)

Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma
por: Khormi, Afaf Y., et al.
Publicado: (2022)

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
por: Oikonomou, Eftychia, et al.
Publicado: (2011)

RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
por: Jebali, Ahlem, et al.
Publicado: (2021)

BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report
por: Giovannoni, Sara, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nkq7qcfs0gv691lpfg534k9ajd